IMMUNITYBIO, INC. (IBRX) Total liabilities 2016–2025
IMMUNITYBIO, INC. (IBRX) total liabilities at each fiscal year-end, per SEC filings.
$1.0BFY2025 · since FY2016: $24.1M → $1.0B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.0B | +15.0% |
| FY2024 | $871.1M | -20.1% |
| FY2023 | $1.1B | +34.3% |
| FY2022 | $812.2M | +13.9% |
| FY2021 | $712.8M | +109.7% |
| FY2020 | $339.9M | +34.1% |
| FY2019 | $253.5M | +605.2% |
| FY2018 | $35.9M | +13.8% |
| FY2017 | $31.6M | +31.2% |
| FY2016 | $24.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice